Replies to post #92823 on Biotech Values

[DewDiligence]

...odds for generic Copaxone to be approved without clinical trials are close to zero…

You’ve said this multiple times on this board, but you’ve never backed it up with a credible argument, IMO.
‘
If the FDA wanted clinical trials to underpin its review of generic Copaxone, the FDA would presumably not have accepted NVS/MNTA’s application for review under the 505j (ANDA) pathway.